News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Global equity markets were mostly flat as trading volume remained light in the past hour.
  • U.S. Treasury yields were little changed after no major economic releases this hour.
  • The dollar was steady versus major currencies with no central bank comments reported.
  • Oil and gold traded in narrow ranges with no new supply or demand drivers.
  • No major geopolitical incidents were reported in the past hour; risk sentiment remained unchanged.
  • Political news flow was quiet with no new legislative or regulatory developments announced.

Latest Articles

Whitestone REIT Shareholders Approve Acquisition by Ares

Whitestone REIT Shareholders Approve Acquisition by Ares

Whitestone REIT's shareholders have approved the all-cash acquisition by Ares Real Estate funds for $19.00 per share, valuing the transaction at approximately $1.7 billion. The deal follows a definitive merger agreement signed in April 2026 and is expected to close around July 14, 2026, subject to customary closing conditions.

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

ImmuCell Corporation announced preliminary unaudited sales results for Q2 and the first six months of 2026, showing 11.5% and 20.9% increases respectively compared to 2025. Growth was primarily driven by a 27.7% domestic sales increase, despite a decline in international sales. The company attributed the growth to strong product availability, a foc…

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

Rani Therapeutics announced a strategic R&D collaboration with PegBio to explore oral delivery of PegBio's novel obesity and metabolic disease molecules using Rani's proprietary RaniPill® platform. This partnership aims to broaden Rani's obesity treatment pipeline by advancing multiple new candidates with differentiated mechanisms of action into cl…

Amneal to Report Second Quarter 2026 Results on July 30, 2026

Amneal to Report Second Quarter 2026 Results on July 30, 2026

Amneal Pharmaceuticals, a diversified global biopharmaceutical company, announced that it will report its second quarter 2026 financial results on July 30, 2026, before the market opens. The company will host a live audio webcast for investors and interested parties to discuss the financial results and operational updates.

Varonis Announces Date of Second Quarter 2026 Financial Results

Varonis Announces Date of Second Quarter 2026 Financial Results

Varonis Systems, a leader in data and AI security, announced the date for its second quarter 2026 financial results release. The company will report results after US market close on July 28, 2026, and hold a conference call to discuss the financial outcomes. The event will be accessible via phone and webcast, with a replay available for one year.

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Denali Therapeutics' CEO Dr. Ryan Watts will deliver the opening address at the 2026 Alzheimer's Association International Conference to showcase breakthroughs in their proprietary TransportVehicle™ platform, enabling biologic drugs to cross the blood-brain barrier. The company is advancing investigational therapies targeting tau and amyloid beta f…

20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

20/20 BioLabs presented its strategy during an investor webinar to advance OneTest™ for Cancer as an affordable multi-cancer early detection blood test targeting Medicare reimbursement under new federal legislation starting 2028. The company emphasized its differentiating serial biomarker tracking technology, real-world evidence generation from hig…

MKS Named by Time as One of America’s Best Companies for 2026

MKS Named by Time as One of America’s Best Companies for 2026

MKS Inc., a global technology provider serving semiconductor manufacturing and specialty industrial applications, has been named one of America’s Best Companies for 2026 by Time and Statista. This marks the second consecutive year MKS received this recognition, which evaluates companies based on employee satisfaction, financial success, and sustain…